DDInter624 DDInter1269
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nateglinide
Efavirenz {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Nateglinide
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Efavirenz {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Amphetamine
Amphetamine {u} (Compound) resembles {v} (Compound) Nateglinide
Efavirenz {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Amphetamine
Amphetamine {u} (Compound) resembles {v} (Compound) Nateglinide
Efavirenz {u} (Compound) causes {v} (Side Effect) Jaundice
Jaundice {u} (Side Effect) is caused by {v} (Compound) Ramipril
Ramipril {u} (Compound) resembles {v} (Compound) Nateglinide
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatic enzyme increased
Hepatic enzyme increased {u} (Side Effect) is caused by {v} (Compound) Vardenafil
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Efavirenz {u} (Compound) causes {v} (Side Effect) Back pain
Back pain {u} (Side Effect) is caused by {v} (Compound) Enalapril
Enalapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Saquinavir
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Sulfinpyrazone
Sulfinpyrazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nateglinide
Efavirenz (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nateglinide (Compound)
Efavirenz (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Efavirenz (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Efavirenz (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Amphetamine (Compound) and Amphetamine (Compound) resembles Nateglinide (Compound)
Efavirenz (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Amphetamine (Compound) and Amphetamine (Compound) resembles Nateglinide (Compound)
Efavirenz (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Ramipril (Compound) and Ramipril (Compound) resembles Nateglinide (Compound)
Efavirenz (Compound) causes Hepatic enzyme increased (Side Effect) and Hepatic enzyme increased (Side Effect) is caused by Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Efavirenz (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Efavirenz (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sulfinpyrazone (Compound) and Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Nateglinide